AptarGroup Shareholders: Ownership Structure, Brands, and Acquisition History
Last updated: Sep-2026Ownership Structure
Stakes approximate based on latest filings.
Ownership Analysis
A conventionally owned public company, AptarGroup is best analyzed, in our view, through the drug-delivery franchise its dispersed owners are backing rather than through any control dynamic. No shareholder controls the company; index funds, Vanguard near 12.5 percent, BlackRock at 9.8 percent, State Street at 4.7 percent, and Victory Capital at 3.8 percent, hold the largest positions, typical of a mid-cap materials company. What this ownership represents, in our assessment, is a stake in a specialized dispensing-systems maker whose value is concentrated in its pharmaceutical business. Across three segments, Pharma, Beauty, and Closures, Aptar supplies the delivery and packaging components that dispense medicines, cosmetics, and consumer products, but the segments differ sharply in quality: Aptar Pharma, which makes drug-delivery systems such as nasal sprays and inhalers, is a high-margin, regulated business where Aptar's components are integral to medicines and switching is difficult, while Beauty and Closures are more competitive consumer-packaging businesses. The dispersed base holds management accountable for growing the valuable Pharma franchise, managing the more competitive consumer segments, and allocating capital toward its highest-return opportunities in drug delivery. Owning AptarGroup is a bet on the durable growth and margins of pharmaceutical drug delivery anchoring a diversified dispensing-systems portfolio, a proposition whose quality rests substantially on the Pharma segment that distinguishes Aptar from ordinary packaging companies.
Direct Owners
Institutional Shareholders
Shareholder Analysis
Investors in AptarGroup own a specialized dispensing-systems company whose value, in our view, is anchored by its high-margin pharmaceutical drug-delivery business. On about 3.78 billion dollars of revenue, the company earns attractive margins in Pharma, where its nasal-spray, inhaler, and injectable delivery systems are integral to how medicines are administered, while its Beauty and Closures segments generate more competitive consumer-packaging returns. Its holders are predominantly index funds, consistent with a mid-cap. In our assessment, the bull case rests on the quality of Aptar Pharma, a high-margin, regulated drug-delivery business with pricing power and secular growth from injectables, nasal delivery, and biologics, its integral role in medicines that creates high switching costs and durable relationships, the diversification its consumer segments provide, and its capital deployment toward drug-delivery growth. The bear case comprises the more competitive, lower-margin nature of the Beauty and Closures segments, exposure to consumer-packaging cyclicality and input costs, competition from larger packaging companies and specialized drug-delivery rivals, and a valuation that reflects the market's appreciation of the Pharma franchise. Shareholders are betting that Aptar Pharma continues to grow at attractive margins, anchoring the portfolio and driving value, while the consumer segments provide diversification, translating the company's leadership in pharmaceutical drug delivery into durable earnings growth, in a business whose pharmaceutical core distinguishes it from ordinary packaging companies and underpins its premium quality.
Brands, Subsidiaries & Companies Owned
| Name | Type | Description |
|---|---|---|
| Aptar Pharma | Brand | Drug delivery and pharmaceutical packaging systems |
| Aptar Beauty | Brand | Dispensing systems for beauty and personal care |
| Aptar Closures | Brand | Food beverage and household closure systems |
| CSP Technologies | Company | Active material science packaging |
| Noble | Company | Drug delivery training devices |
| FusionPKG | Company | Prestige beauty packaging and dispensing |
Portfolio Analysis
AptarGroup competes on the technical sophistication and regulatory integration of its dispensing systems, and in our view the pharmaceutical drug-delivery business is what elevates its competitive identity above ordinary packaging. Its portfolio spans Aptar Pharma, which makes drug-delivery systems such as nasal sprays, inhalers, and injectable components, augmented by Noble in drug-delivery training devices, Aptar Beauty, which supplies dispensing systems for beauty and personal care alongside prestige-packaging capabilities from FusionPKG, and Aptar Closures, which makes closures for food, beverage, and household products, supported by active-material-science capabilities from CSP Technologies. The strategic proposition, in our assessment, is to combine a high-value, regulated drug-delivery business, where Aptar's systems are integral to medicines and deeply embedded in regulatory approvals, with broader consumer-dispensing capabilities that provide scale and diversification. Aptar's competitive strengths are the technical sophistication and regulatory integration of its Pharma drug-delivery systems, which create high switching costs and durable customer relationships, its scale across dispensing and packaging, and its material-science and digital-health capabilities. In our view, the company's competitive identity rests primarily on Aptar Pharma, whose systems are integral to how medicines are delivered and whose regulatory embeddedness provides a genuine moat, distinguishing Aptar from commodity packaging companies and anchoring the differentiated, higher-margin foundation of its diversified dispensing-systems franchise.
Market Share & Competitors
Bubble size reflects relative market share.
| Company | Market Share | Revenue | Key Strength |
|---|---|---|---|
| AptarGroup ★ | N/A | $3.777B FY2025 | Drug delivery and dispensing systems leader |
| Silgan Holdings | N/A | $6.1B FY2025 | Rigid packaging and dispensing systems producer |
| Berry Global | N/A | $13.8B FY2025 | Plastic packaging and engineered materials supplier |
| West Pharmaceutical Services | N/A | $3.0B FY2025 | Injectable drug packaging and delivery supplier |
| Gerresheimer | N/A | $2.2B FY2025 | Pharmaceutical packaging and drug delivery producer |
Competitive Analysis
Competing in drug-delivery and dispensing systems, AptarGroup holds, in our view, a strong competitive position in pharmaceutical delivery and a more contested one in consumer packaging. In drug delivery it competes against specialized players like West Pharmaceutical Services and Gerresheimer, while its consumer segments compete against packaging companies such as Silgan Holdings and the much larger Berry Global. Aptar's competitive advantages are strongest in Pharma, where the technical sophistication and regulatory integration of its drug-delivery systems create high switching costs, durable relationships, and pricing power, differentiating it sharply from commodity packaging; in Beauty and Closures, its scale and capabilities are advantages but competition is more intense and margins lower. The competitive challenges are the commoditization and cyclicality of the consumer-packaging segments, input-cost and pricing pressure, competition from larger packaging companies and specialized drug-delivery rivals, and the need to keep innovating in regulated drug delivery. In our assessment, AptarGroup competes most effectively in pharmaceutical drug delivery, where its regulatory embeddedness and technical differentiation provide a genuine competitive moat, while its consumer segments compete on scale and capability in more contested markets. Its overall competitive strength rests on the Pharma franchise, and sustaining its position depends on continuing to innovate in drug delivery, deepen its regulatory integration, and manage the more competitive consumer segments, with the pharmaceutical business the durable foundation of its competitiveness.
Acquisitions
Bubble size reflects relative deal value.
| Company Acquired | Deal Value | Year | Description |
|---|---|---|---|
| CSP Technologies | $555M | 2018 | Added active material science packaging |
| Noble | $80M | 2019 | Added drug delivery training devices |
| Voluntis | $62M | 2021 | Added digital therapeutics capabilities |
| Sommaplast | N/A | 2025 | Expanded beauty packaging production |
Acquisitions Analysis
Targeted acquisitions have extended AptarGroup's capabilities in drug delivery, materials, and digital health, and in our analysis this focused dealmaking reflects a deliberate strengthening of its higher-value businesses. Since becoming independent in 1992, Aptar has expanded through selective acquisitions rather than transformative mergers: the 2018 purchase of CSP Technologies for 555 million dollars added active-material-science packaging capabilities, the 2019 acquisition of Noble for 80 million dollars added drug-delivery training devices, the 2021 acquisition of Voluntis for 62 million dollars extended Aptar into digital therapeutics, and 2025 brought increased ownership in BTY and the acquisition of Sommaplast to expand beauty packaging. These deals have consistently reinforced Aptar's capabilities, particularly in its higher-value pharmaceutical and material-science areas, complementing organic development. For investors, the key insight is that Aptar's acquisitions are targeted, capability-adding deals that strengthen its differentiated businesses, especially drug delivery and materials, rather than scale-driven combinations in commodity packaging. In our assessment, this disciplined acquisition strategy has enhanced the quality of Aptar's portfolio, adding regulated, higher-margin capabilities and digital-health optionality, and its future value creation depends more on organic growth in pharmaceutical drug delivery and disciplined capital deployment than on transformative acquisitions, consistent with a company whose strategy centers on strengthening its differentiated, high-value franchises.
Acquisition Timeline
Merger & Spin-off History
Merger & Spin-off Analysis
Independent through a 1992 separation and expanded through targeted acquisitions, AptarGroup's corporate structure, in our view, reflects a focused dispensing-systems company that has strengthened its higher-value businesses. Its dispensing heritage began with the Seaquist family's valve business in 1947, and AptarGroup became an independent public company in 1992 following separation from Pittway. Rather than pursue a large corporate merger, it has expanded its structure through targeted acquisitions in active materials, drug-delivery services, digital health, and beauty packaging, adding CSP Technologies, Noble, Voluntis, and others, while organizing itself into three segments: Pharma, Beauty, and Closures. For investors, the structural story is one of a dispensing-systems company that gained independence and then selectively enhanced its capabilities, particularly in its higher-value pharmaceutical and material-science areas, through disciplined acquisitions. In our assessment, AptarGroup's structure, three segments spanning pharmaceutical drug delivery, beauty dispensing, and consumer closures, is coherent and reflects its strategy of anchoring a diversified dispensing business with a high-value Pharma franchise. Its structural evolution since independence has been one of focused enhancement rather than transformation, adding regulated, higher-margin capabilities to strengthen the differentiated core, and its structure supports a strategy centered on the pharmaceutical drug-delivery business that distinguishes it from commodity packaging companies.
Ownership History
Ownership History Analysis
From a family dispensing-valve business to a specialized drug-delivery leader, AptarGroup's history, in our view, reflects a steady elevation toward higher-value markets. The Seaquist family founded a dispensing-valve business in 1947, and AptarGroup became an independent public company in 1992 after separating from Pittway, beginning its life as a focused dispensing-systems maker. Over the following decades, the company expanded across pharma, beauty, and consumer markets and deliberately strengthened its higher-value capabilities through targeted acquisitions, adding active-material science with CSP Technologies, drug-delivery training devices with Noble, and digital therapeutics with Voluntis, while its pharmaceutical drug-delivery business grew into its most valuable segment. By 2025 it was further expanding its beauty and pharmaceutical capabilities through additional acquisitions. Generating about 3.78 billion dollars in revenue as a widely held company, AptarGroup is a specialized dispensing-systems maker anchored by its high-margin Pharma franchise. Its history, in our assessment, is that of a family dispensing business that became an independent public company and steadily elevated itself toward the higher-value, regulated drug-delivery market, where its systems are integral to medicines, building a differentiated pharmaceutical franchise that distinguishes it from commodity packaging companies and anchors the quality of its diversified dispensing-systems portfolio.
Ownership Explained
Trading on the NYSE under ATR, AptarGroup is a widely held maker of drug-delivery and dispensing systems with no controlling shareholder, its largest holders being index funds led by Vanguard and BlackRock. Crystal Lake, Illinois-based and tracing its dispensing-valve heritage to 1947, the company generates about 3.78 billion dollars of revenue with roughly 14,000 employees. Its business spans three segments: Aptar Pharma, which makes high-value drug-delivery systems such as nasal sprays and inhalers, Aptar Beauty, which supplies dispensing systems for beauty and personal care, and Aptar Closures, which makes closures for food, beverage, and household products. The Pharma segment is the company's most valuable and highest-margin business.
Owned broadly by index funds with no dominant holder, ATR offers a claim on a specialized dispensing-systems maker whose crown jewel is its pharmaceutical drug-delivery business. Ownership means participating in the economics of a company that supplies critical delivery and packaging components across pharma, beauty, and consumer markets, with the high-margin, regulated Pharma segment providing quality and pricing power. What shareholders are backing is a business that increasingly leans on drug delivery, where its systems are integral to how medicines are administered, complemented by more competitive consumer-packaging segments. The investment case rests on the growth and margins of Pharma anchoring a diversified dispensing-systems portfolio.